IPCA Laboratories Ltd has introduced ‘Diulcus,’ a new product designed to tackle the challenges associated with Diabetic Foot Ulcer (DFU).
~ Diulcus, developed by NovaLead Pharma, shows promising results in clinical trials with a 77.20% ulcer closure rate ~ ~Approved by CDSCO and partially funded...